Marginal Zone Lymphoma - 6 Studies Found Terminated : Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma : Follicular Lymphoma Chronic Lymphocytic Leukemia Small Lym : 2014-10-03 : Drug: GS-9901 GS-9901 tablets administered orally Terminated : Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma : Lymphoma : 2008-10-12 : Drug: Rituximab 375 mg/m2 IV i Terminated : Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma : Lymphoma : 2012-01-06 : Drug: clarithromycin, oral, high dose 2 g/day clarithromycin (once a day) for 14 days followed by 7 days Completed : Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia : Waldenström Macroglobulinemia Lymphoplasmacytic Lymphoma Drug: Chlorambucil Chlorambuci RECRUITING : FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role : Marginal Zone Lymphoma : 2024-11-21 RECRUITING : MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) : Follicular Lymphoma and Marginal Zone Lymphoma : 2024-11-21 : 1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycl
